56 completed, 14 terminated, 10 recruiting, 8 active not recruiting. 96 Phase 2, 25 Phase 1, 2 Phase 3.
Follow Thrombocytosis: new trials by email Literature Review of Thrombocytosis trials Research Report on Thrombocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2026-09-29 | 2026-05-06 |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 78 | 2025-08-14 | 2026-10-27 |
| A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial STP938 - Essential Thrombocythaemia | Phase 2 | Recruiting | Step Pharma, SAS | 50 | 2025-06-18 | 2026-06-16 |
| Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis JBI-802 - Essential Thrombocythemia (ET), Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) | Phase 1 / Phase 2 | Recruiting | Jubilant Therapeutics Inc. | 30 | 2024-10-21 | 2026-06-03 |
| MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial Methotrexate (MTX) - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 54 | 2024-10-02 | 2025-12-17 |
| Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET Peginterferon α-2b injection - Essential Thrombocythemia | Phase 2 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 27 | 2024-08-29 | 2025-11-17 |
| Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia | Phase 2 | Recruiting | University of Southern California | 30 | 2024-03-01 | 2026-03-27 |
| Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | Phase 2 | Terminated | Mayo Clinic | 3 | 2023-02-20 | 2024-09-19 |
| A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET Ropeginterferon alfa-2b-njft (P1101) - Essential Thrombocythemia | Phase 2 | Active not recruiting | PharmaEssentia | 91 | 2022-09-29 | 2025-08-13 |
| Ruxolitinib in Thrombocythemia and Polycythemia Vera Ruxolitinib - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Recruiting | Massachusetts General Hospital | 60 | 2022-03-21 | 2026-01-08 |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms N-Acetylcysteine - Myeloproliferative Neoplasm, MPN | Phase 1 / Phase 2 | Recruiting | University of California, Irvine | 27 | 2022-01-03 | 2026-03-10 |
| An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 81 | 2021-12-15 | 2025-09-22 |
| Two Step Haplo With Radiation Conditioning Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Thomas Jefferson University | 63 | 2021-10-25 | 2025-10-30 |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) itacitinib - Myelofibrosis, Polycythemia Vera | Phase 2 | Completed | Incyte Corporation | 4 | 2021-07-12 | 2025-09-02 |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
| A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy APG-1252, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Withdrawn | Ascentage Pharma Group Inc. | 2020-12-15 | 2022-07-12 | |
| IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) IMG-7289 - Essential Thrombocythemia, Polycythemia Vera | Phase 2 | Active not recruiting | Terrence J Bradley, MD | 4 | 2020-10-02 | 2026-01-07 |
| Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) Bomedemstat - Essential Thrombocythemia | Phase 2 | Completed | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 73 | 2020-09-08 | 2026-05-04 |
| Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 IMG-7289 - Thrombocythemia, Essential | Phase 2 | Active not recruiting | The University of Texas Health Science Center at San Antonio | 9 | 2020-04-09 | 2026-10-22 |
| Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Decitabine, Ruxolitinib, Fedratinib - Acute Myeloid Leukemia, Essential Thrombocythemia | Phase 2 | Recruiting | University of Washington | 25 | 2020-03-24 | 2026-09-17 |
Showing 20 of 96. Sign in to see all of them.
Thrombocythemia, Essential (88) · Polycythemia Vera (77) · Primary Myelofibrosis (67) · Myeloproliferative Disorders (59) · Leukemia, Myeloid, Acute (31) · Leukemia, Myelomonocytic, Chronic (31) · Myelodysplastic Syndromes (29) · Leukemia (26) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (26) · Leukemia, Lymphocytic, Chronic, B-Cell (25) · Multiple Myeloma (22) · Leukemia, Myeloid, Accelerated Phase (21) · Lymphoma, Non-Hodgkin (21) · Blast Crisis (20) · Congenital Abnormalities (20)
Hemic and Lymphatic Diseases (96) · Blood Platelet Disorders (94) · Bone Marrow Diseases (92) · Hematologic Diseases (90) · Hemorrhagic Disorders (87) · Blood Coagulation Disorders (86) · Neoplasms by Site (79) · Neoplasms (78) · Bone Marrow Neoplasms (77) · Hematologic Neoplasms (77) · Neoplasms by Histologic Type (42) · Leukemia, Myeloid (41) · Chronic Disease (40) · Disease Attributes (40)
fludarabine phosphate (19) · Cyclophosphamide (18) · Peripheral Blood Stem Cell Transplantation (16) · Busulfan (14) · Whole-Body Irradiation (11) · Cyclosporine (10) · Methotrexate (10) · Mycophenolic Acid (10) · Tacrolimus (10) · ruxolitinib (10) · Antilymphocyte Serum (7) · Biopsy (6) · fludarabine (6) · Radiotherapy (5) · Specimen Handling (5)
Fred Hutchinson Cancer Center (11) · M.D. Anderson Cancer Center (6) · National Cancer Institute (NCI) (6) · Mayo Clinic (5) · H. Lee Moffitt Cancer Center and Research Institute (3) · Incyte Corporation (3) · Italfarmaco (3) · Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · OHSU Knight Cancer Institute (2) · Ronald Hoffman (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Sierra Oncology LLC - a GSK company (2) · Asan Medical Center (1) · Ascentage Pharma Group Inc. (1)
United States (73) · Germany (12) · Italy (11) · United Kingdom (10) · France (9) · Australia (7) · Canada (6) · Belgium (4) · Denmark (3) · Netherlands (3) · Poland (3) · Spain (3) · Switzerland (3) · Austria (2) · China (2)
Ruben A. Mesa, MD (4) · Alessandro Rambaldi, MD (3) · Ayalew Tefferi, MD (2) · H. Joachim Deeg, MD (2) · Jorge Cortes, MD (2) · Teresa Field, MD, PhD (2) · Uday Popat, MD (2) · Usama Gergis, MD (2) · Abhishek A. Mangaonkar, M.B.B.S. (1) · Albert Assad, MD (1) · Amy E DeZern, MD (1) · Anand A Patel (1) · Andrew Roberts, M.D. (1)
PMID 32499241, PMID 11468154, PMID 19841031, PMID 20651074, PMID 20843246, PMID 22718840, PMID 22943924, PMID 23890523, PMID 24362550, PMID 24903629, PMID 25047979, PMID 25563429, PMID 25762180, PMID 26210442, PMID 26332546, PMID 27479177, PMID 28291640, PMID 28622623, PMID 29152412, PMID 29544547, PMID 30409796, PMID 30630975, PMID 32634234, PMID 32732354, PMID 33609248, PMID 36564535, PMID 36881782, PMID 36911725, PMID 37345627, PMID 37422688, PMID 37530627, PMID 37592092, PMID 38259250, PMID 40330782, PMID 40775758, PMID 41758981, PMID 42306077, PMID 9326205
P30CA015083 (4), P01CA015396 (2), P01CA018029 (2), P01CA108671 (2), P30CA006973 (2), P30CA015704 (2), 2004 (1), 2018 (1), 2019 (1), N01CM17104 (1), N01CM62201 (1), P01CA078902 (1), P30CA014089 (1), P30CA014599 (1), P30CA016058 (1)